Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Accounts Payables (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Accounts Payables for 6 consecutive years, with $463458.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 76.45% to $463458.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $463458.0, a 76.45% decrease, with the full-year FY2024 number at $1.4 million, down 29.9% from a year prior.
  • Accounts Payables was $463458.0 for Q3 2025 at Ensysce Biosciences, down from $1.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.1 million in Q2 2021 to a low of $301104.0 in Q4 2021.
  • A 5-year average of $1.3 million and a median of $1.0 million in 2025 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 1818.74% in 2021; the steepest drop was 90.87% in 2021.
  • Ensysce Biosciences' Accounts Payables stood at $301104.0 in 2021, then skyrocketed by 877.67% to $2.9 million in 2022, then plummeted by 34.23% to $1.9 million in 2023, then decreased by 29.9% to $1.4 million in 2024, then tumbled by 65.85% to $463458.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Accounts Payables are $463458.0 (Q3 2025), $1.0 million (Q2 2025), and $615295.0 (Q1 2025).